

18th November, 2011

The Stock Exchange, Mumbai
Rotunda Building, 2nd Floor,
Dalal Street,
Mumbai – 400 001

AJANTA HOUSE
Charkop, Kandivli (W),
MUMBAI – 400 067, INDIA
Tel. : (+91)22-6606 1000
Fax : (+91)22-6606 1200 / 300
E-mail : info@ajantapharma.com
Website : www.ajantapharma.com

Dear Sir,

Scrip Code: BSE – AJANPHA 32331
NSE – AJANPHARM EQ

We wish to inform the stock exchanges that the company has received letter dated 18th November, 2011 from the one of the Promoter viz., Mrs. Smriti Rajesh Agrawal (copy enclosed) which is self-explanatory for your information and ready reference please.

Kindly treat this letter as compliance from the company under Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, SEBI (Prohibition of Insider Trading) Regulations, 1992 as well as under any other statutory regulations and guidelines as may be applicable.

Kindly acknowledge receipt.

Thanking You,

Yours faithfully,
For **AJANTA PHARMA LIMITED**



HIRAL MEHTA

Dy. Manager - Secretarial

c.c. : National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051.

Encl.: a/a.

18th November, 2011

The Company Secretary
Ajanta Pharma Limited
"Ajanta House",
Charkop, Kandivli (West)
Mumbai – 400 067

Sub.: Purchase of 1000 number of shares of Ajanta Pharma Limited (APL)

I wish to inform you that as per SEBI (Prohibition of Insider Trading) Regulations, 1992 and Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, I have purchased 1000 number shares of Ajanta Pharma Limited (APL).

My aggregate shareholding in APL was 202287 number shares being 73% of the paid up share capital of the company prior to the said purchase of shares which has now increased to 203287 number shares being 74% of the total paid up share capital of the company.

This is submitted for your information and records please.

Thanking you,

Yours faithfully,



SMRITI RAJESH AGRAWAL

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Ajanta Pharma Limited		
2. Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Smriti Rajesh Agrawal		
3. Whether the acquirer belongs to Promoter/Promoter group	Promoter		
4. Name(s) of the Stock Exchange(s) where the shares of TC are Listed	The Stock Exchange, Mumbai & National Stock Exchange of India		
5. Details of the acquisition / disposal/holding of shares/voting rights/holding of the Acquirer and PAC	Number	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC (*)
Before the acquisition/ disposal under consideration, holding of :	202287	1.73%	
a) Shares carrying voting rights			-
b) Voting rights (VR) otherwise than by shares			-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)			-
Total (a+b+c)	202287	1.73%	
Details of acquisition/ sale	1000	0.01	
a) Shares carrying voting rights acquired/ sold			-
b) VRs acquired /sold otherwise than by shares			-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding			-

in each category) acquired/sold			
Total (a+b+c)	1000	0.01	
After the acquisition/ sale , holding of:	203287	1.74%	
a) Shares carrying voting rights			
b) VRs otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition.			
Total (a+b+c)	203287	1.74%	
6. Mode of acquisition / sale (e.g. open market / off market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market		
7. Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	17/11/11		
8. Equity share capital / total voting capital of the TC before the said acquisition / sale	1,17,08,500	100%	
9. Equity share capital/ total voting capital of the TC after the said acquisition / sale	1,17,08,500	100%	
10. Total diluted share/voting capital of the TC after the said acquisition/sale.	1,17,08,500	100%	

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the acquirer/~~seller~~/ Authorised Signatory



Place: Mumbai

Date: 18th November, 2011